- Aprea Therapeutics Announces Presentations on A Novel Macrocyclic ATR Inhibitor, ATRN-119
- Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% DCR After 24-Weeks of Treatment with (Z)-Endoxifen
- AZD1390 With Radiotherapy Shows Manageable Safety Profile and Preliminary Efficacy for Patients with Glioblastoma in Phase I Trial
- Bispecific Immune Checkpoint Inhibitor Improves Survival in Gastric Cancer Patients Regardless of PD-L1 Status
- BriaCell Showcases Data Demonstrating Unmatched PFS and Clinical Efficacy in ADC Resistant and CNS Metastatic Breast Cancer
- Edison Oncology Reports Promising Interim Data from Ongoing Orotecan® Clinical Trial for Recurrent Pediatric Cancers
- EpicentRx to Present Positive Phase 2a Clinical Data with its AdAPT-001 TGF-β Trap Program in Checkpoint Inhibitor Resistant Patients
- Geneos Therapeutics Announces Positive Phase 1/2 Data for GT-30 Trial of Personalized Therapeutic Cancer Vaccine
- KRAZATI (adagrasib) in Combination with Cetuximab Demonstrates Clinically Meaningful Activity in Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or mCRC
- Linvoseltamab Pivotal Data Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
- Medicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study
- Merck, Kelun’s Anti-TROP2 ADC SKB264/sac-TMT Shows Early Promise in Gastric Cancer
- Notable Labs Presents the Design Plan for the PPMP-Enabled Phase 2 Trial with Volasertib for Relapsed/Refractory AML
- Nurix Therapeutics Reports First Clinical Evidence of CNS Activity of NX-5948, a Brain-Penetrant BTK Degrader in Development for B Cell Malignancies
- Poseida Therapeutics Presents New Phase 1 Data Supporting Potential of P-BCMA-ALLO1 Allogeneic CAR-T Therapy to Benefit Broad Range of Patients with Multiple Myeloma
- RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients
- Results of Exploratory Biomarker Analysis of Pivotal Clinical Trial ASTRUM-005 of Serplulimab
- The positive interim analysis results from the Phase III clinical study of Akeso’s Cadonilimab (PD-1/CTLA-4 BsAb) plus chemotherapy as first-line treatment for advanced gastric cancer presented
- Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients with Resected Pancreatic Cancer
- Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer
- TransThera announces clinical data of tinengotinib to treat patients with advanced solid tumors harboring actionable FGFR1-3 alterations
Menu
